FDA — authorised 27 May 2016
- Application: BLA761029
- Marketing authorisation holder: BIOGEN
- Local brand name: ZINBRYTA
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 Anti-IL2R AB in United States
FDA authorised Anti-IL2R AB on 27 May 2016
Marketing authorisation
Other Immunology approved in United States
Frequently asked questions
Is Anti-IL2R AB approved in United States?
Yes. FDA authorised it on 27 May 2016.
Who is the marketing authorisation holder for Anti-IL2R AB in United States?
BIOGEN holds the US marketing authorisation.